Bernstein Maintains a Hold Rating on Merck & Co (MRK)

Group 1 - Merck & Co., Inc. is considered one of the best and cheap stocks to buy currently [1] - The company is set to announce its fiscal third quarter results on October 30 [2] - In the second quarter of 2025, Merck reported an EPS of $2.13, exceeding Wall Street estimates by $0.10, while revenue was $15.81 billion, a decline of 1.90% and falling short of expectations by $66.69 million [2] Group 2 - Management has updated its full-year sales guidance for 2025, now expecting revenue between $64.3 billion and $65.3 billion, revised from the previous guidance of $64.1 billion to $65.6 billion [3] - Merck is a global healthcare company involved in the development and sale of prescription medicines, vaccines, and animal health products [3]